CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 1,549 enrolled
Drug / intervention
BI 10773 +3 moredrug
Likely dose
Glimepiride 4 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01167881
NCT01167881Phase 3Completed

A Phase III Randomised, Double-blind, Active-controlled Parallel Group Efficacy and Safety Study of BI 10773 Compared to Glimepiride Administered Orally During 104 Weeks With a 104 Week Extension Period in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control Despite Metformin Treatment

Boehringer Ingelheim·interventional·Posted Jul 22, 2010·Updated Sep 2, 2016

In Brief

A Phase 3 clinical trial evaluating BI 10773, Glimepiride, and 1 other intervention for Diabetes Mellitus, Type 2. Completed, enrolled 1,549 participants across 182 sites in 23 countries.

Detailed Summary

This is a pivotal phase III study, mandatory to seek approval by regulatory authorities for BI 10773 as an anti-diabetic agent compared to an active comparator in patients with type 2 diabetes mellitus and insufficient glycaemic control.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesArgentina, Austria, Canada, Colombia, Czechia, Finland, Hong Kong, India, Italy, Malaysia, Mexico, Netherlands, Norway, Philippines, Portugal, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, United Kingdom, United States

Timeline

Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJul 22, 2010
Enrollment StartAug 1, 2010
Primary CompletionAug 1, 2013
Study CompletionAug 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 15.9 years ago

Interventions

BI 10773drug

Medium dose once daily

Glimepiridedrug

1-4 mg once daily

Placebodrug

Placebo matching BI 10773

Placebodrug

Placebo matching Glimepiride